Hexagon Bio Information

Hexagon Bio is a biopharmaceutical company pioneering the discovering novel payloads for antibody-drug conjugates (ADCs) to address critical unmet needs in oncology. Leveraging a proprietary platform, the company mines cytotoxic small molecules from microbial genomes for use as ADC payloads. Advances in DNA sequencing have enabled the identification of both existing ADC payloads—such as topoisomerase and tubulin inhibitors—and novel payload mechanisms targeting essential cancer pathways such as protein translation. Hexagon Bio is advancing a pipeline of next-generation ADC candidates with novel payloads designed to treat a wide range of solid tumors and hematological malignancies.